These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 29620166)

  • 1. Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell lines.
    Wang X; Goldstein D; Crowe PJ; Yang JL
    Int J Oncol; 2018 Jun; 52(6):2143-2154. PubMed ID: 29620166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma.
    Wang X; Goldstein D; Crowe PJ; Yang M; Garrett K; Zeps N; Yang JL
    Oncotarget; 2016 Apr; 7(16):21496-509. PubMed ID: 26909593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma.
    Chen W; Shen X; Xia X; Xu G; Ma T; Bai X; Liang T
    Liver Int; 2012 Jan; 32(1):70-7. PubMed ID: 22098470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct apoptotic blocks mediate resistance to panHER inhibitors in HER2+ breast cancer cells.
    Karakas B; Ozmay Y; Basaga H; Gul O; Kutuk O
    Biochim Biophys Acta Mol Cell Res; 2018 Aug; 1865(8):1073-1087. PubMed ID: 29733883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of STAT3 inhibition on survival of osteosarcoma cell lines.
    Wang X; Goldstein D; Crowe PJ; Yang JL
    Anticancer Res; 2014 Nov; 34(11):6537-45. PubMed ID: 25368256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384.
    Zhu Y; Shah K
    Cancer Biol Ther; 2014 Jun; 15(6):815-22. PubMed ID: 24658109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
    Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
    Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dacomitinib, a new pan-EGFR inhibitor, is effective in killing ovarian cancer cells.
    Xu L; Wu H; Jiang C; Wang H; Gao B; Yan S; Qi Y; Zhou S
    Discov Med; 2016 Nov; 22(122):297-309. PubMed ID: 28009971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC).
    Codony-Servat C; Codony-Servat J; Karachaliou N; Molina MA; Chaib I; Ramirez JL; de Los Llanos Gil M; Solca F; Bivona TG; Rosell R
    Oncotarget; 2017 Jul; 8(29):47305-47316. PubMed ID: 28521301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of STAT3 activity delays obesity-induced thyroid carcinogenesis in a mouse model.
    Park JW; Han CR; Zhao L; Willingham MC; Cheng SY
    Endocr Relat Cancer; 2016 Jan; 23(1):53-63. PubMed ID: 26552408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [STAT signaling pathway mediates high glucose induced cardiac fibroblasts proliferation and collagen deposition in vitro].
    Dai B; Zhu M; Su W; Qiu M; Zhang H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2015 May; 43(5):442-7. PubMed ID: 26419992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agent.
    Ball DP; Lewis AM; Williams D; Resetca D; Wilson DJ; Gunning PT
    Oncotarget; 2016 Apr; 7(15):20669-79. PubMed ID: 26942696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines.
    Yar Saglam AS; Alp E; Elmazoglu Z; Menevse S
    Hum Exp Toxicol; 2016 May; 35(5):526-43. PubMed ID: 26183715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes.
    Zhang X; Yue P; Fletcher S; Zhao W; Gunning PT; Turkson J
    Biochem Pharmacol; 2010 May; 79(10):1398-409. PubMed ID: 20067773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers.
    Deng XS; Wang S; Deng A; Liu B; Edgerton SM; Lind SE; Wahdan-Alaswad R; Thor AD
    Cell Cycle; 2012 Jan; 11(2):367-76. PubMed ID: 22189713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma.
    Ma J; Wang S; Zhao M; Deng XS; Lee CK; Yu XD; Liu B
    BMC Cancer; 2011 Jun; 11():255. PubMed ID: 21679466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells.
    Chen CL; Loy A; Cen L; Chan C; Hsieh FC; Cheng G; Wu B; Qualman SJ; Kunisada K; Yamauchi-Takihara K; Lin J
    BMC Cancer; 2007 Jun; 7():111. PubMed ID: 17598902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells.
    Momeny M; Esmaeili F; Hamzehlou S; Yousefi H; Javadikooshesh S; Vahdatirad V; Alishahi Z; Mousavipak SH; Bashash D; Dehpour AR; Tavangar SM; Tavakkoly-Bazzaz J; Haddad P; Kordbacheh F; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Cell Oncol (Dordr); 2019 Aug; 42(4):491-504. PubMed ID: 31025257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo.
    Ren W; Korchin B; Zhu QS; Wei C; Dicker A; Heymach J; Lazar A; Pollock RE; Lev D
    Clin Cancer Res; 2008 May; 14(9):2785-95. PubMed ID: 18451246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells.
    Momeny M; Zarrinrad G; Moghaddaskho F; Poursheikhani A; Sankanian G; Zaghal A; Mirshahvaladi S; Esmaeili F; Eyvani H; Barghi F; Sabourinejad Z; Alishahi Z; Yousefi H; Ghasemi R; Dardaei L; Bashash D; Chahardouli B; Dehpour AR; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Sci Rep; 2017 Jun; 7(1):4204. PubMed ID: 28646172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.